A Syfovre eye side effects cases presentation was one of the most important at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco in early November.
William J. Johnson, M.D., of the Wolfe Clinic in Iowa, reported on Syfovre eye side effects cases ranging from hemorrhagic occlusive vasculitis-type inflammation with continued blindness to uveitis to vision loss to symptomatic floaters.
Dr. Johnson reported that “One of the patients experienced hemorrhagic occlusive vasculitis-type inflammation and continues to have no light perception — clinical terminology for blindness — in the treated eye”, according to this November 3, 2023, Managed Healthcare Executive news report, “Details on 5 Cases of Complications From Syfovre Injections | AAO 2023”.
We have been following this still-developing drug safety issue involving Syfovre eye side effects cases since July 2023. Our most recent Drug Injury Watch article, “Apellis Updates Number of Syfovre Retinal Vasculitis Cases But Provides No Further ‘Explanation'”, was posted last month, in mid-October 2023.
At present, we are investigating Syfovre drug injury lawsuits against Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre, for patients who developed occlusive retinal vasculitis, eye inflammation, vision loss, or blindness after receiving Syfovre injections.[Read article in full at original source]
Strictly Confidential, No Obligation